Clinical Trials Logo
  1. Home
  2. Solid Tumor
  3. NCT03013218
  4. Details
NCT03013218 Clinical Trial

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Solid Tumor Clinical Trial

Official title:
A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT03013218
Other study ID # AT148001
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date February 3, 2017
Est. completion date December 1, 2024

Study information
Verified date March 2024
Source ALX Oncology Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma

Description:

This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of evorpacept (ALX148). The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part 2 will include an initial dose escalation portion followed by a dose expansion portion. Approximately 184 adult patients are expected to be enrolled in the study.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 174
Est. completion date December 1, 2024
Est. primary completion date February 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available.. - Adequate Bone Marrow Function. - Adequate Renal & Liver Function. - Adequate Performance Status Exclusion Criteria: - Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids. - Previous high-dose chemotherapy requiring allogenic stem cell rescue. - Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Evorpacept (ALX148)
Evorpacept (ALX148)
• Pembrolizumab
Keytruda
• Trastuzumab
Herceptin
• Rituximab
Rituxan
• Ramucirumab + Paclitaxel
Standard of care chemotherapy
• 5-FU + Cisplatin
Standard of care chemotherapy

Locations
Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seongnam
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital, Yonsei University Seoul
United States Dana Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States University of Colorado Denver Denver Colorado
United States START-Midwest Grand Rapids Michigan
United States Yale University New Haven Connecticut
United States Seattle Cancer Care Alliance Seattle Washington

Sponsors (1)
Lead Sponsor Collaborator
ALX Oncology Inc.

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicities (Number of participants with a DLT) Number of participants with a DLT Up to 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2